Current Licensing
Opportunities
Curated deals available through the BioRich International network. Request details on any opportunity — our team will follow up within 1–2 business days.
HER2-targeted ADC
Novel HER2-targeted antibody-drug conjugate with differentiated linker-payload technology. Phase I dose-escalation complete; favorable tolerability profile demonstrated in first two cohorts.
Oral GLP-1 Receptor Agonist
Once-daily oral GLP-1 receptor agonist in Phase II for type 2 diabetes and obesity. Strong Phase I PK/PD data. Seeking North American commercialization partner.
Enzyme Replacement Therapy
Recombinant enzyme replacement therapy for lysosomal storage disorder. Phase II completed with statistically significant primary endpoint. Regulatory path to NDA/BLA well defined.
IL-17A/F Bispecific Antibody
Bispecific antibody co-targeting IL-17A and IL-17F for moderate-to-severe psoriasis and psoriatic arthritis. Phase I safety and tolerability data available.
4th Generation CAR-T
Next-generation armored CAR-T cell therapy for relapsed/refractory multiple myeloma. Phase I/II enrollment ongoing; early efficacy signals reported.
NLRP3 Inflammasome Inhibitor
Selective NLRP3 inflammasome inhibitor with brain-penetrant properties. In vivo efficacy in Alzheimer's and Parkinson's disease models. Seeking IND-enabling study partner or full licensee.
KRAS G12C Inhibitor
Chinese pharmaceutical company seeking in-licensing rights for an approved or Phase III KRAS G12C inhibitor for the China market. Strong commercial infrastructure; full regulatory support.
PCSK9 Monoclonal Antibody
Established Chinese cardiovascular specialty company seeking in-licensing rights to an approved or late-stage PCSK9 inhibitor. Proven commercial team in tier 1 and tier 2 cities.
KRAS G12V Inhibitor
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
US/EU buyer disease-area mandate for ANCA-associated vasculitis (GPA, MPA, EGPA). Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
US/EU companies are running an active roadshow to in-license novel, potentially disease-modifying therapies for rare and specialty movement disorders, motor neuron diseases, and rare epilepsies. Open to small and large molecules and siRNA; preclinical-stage assets acceptable and any stage considered. Ex-China / global rights preferred.
TRAIL Agonist
US/EU buyer seeking to in-license TRAIL-agonist programs from PCC through Phase II; indication flexible. Ex-China / global rights preferred.
siRNA / Antisense Oligonucleotide
Well-established US/EU fund seeking siRNA, antisense oligonucleotide, and small-nucleic-acid programs across any disease area; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license cardiovascular and kidney disease programs across modalities (small molecule, large molecule, siRNA, peptide, antisense); preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Polycythemia Vera. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Von Willebrand Disease. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Warm Autoimmune Hemolytic Anemia. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
Energy expenditure / metabolic (non-appetite-suppression)
US/EU buyer seeking to in-license small-molecule weight-loss programs, oral formulations preferred, that drive weight loss by boosting energy metabolism or energy expenditure rather than traditional appetite-suppression mechanisms. Preclinical acceptable. Ex-China / global rights preferred.
CHRM4 Inhibitor
US/EU buyer target-interest mandate for CHRM4 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
COX / 5-LOX Inhibitor
US/EU buyer target-interest mandate for COX / 5-LOX Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
FcRn Inhibitor
US/EU buyer target-interest mandate for FcRn Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
IFN-gamma Inhibitor
US/EU buyer target-interest mandate for IFN-gamma Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAK2 V617F Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for JAK2 V617F Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
LNK Inhibitor
US/EU buyer target-interest mandate for LNK Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
AKT1 Inhibitor
US/EU buyer target-interest mandate for AKT1 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
APJ Antagonist
US/EU buyer target-interest mandate for APJ Antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
BMP9 Recombinant Protein (mimic endogenous BMP9)
US/EU buyer target-interest mandate for BMP9 Recombinant Protein (mimic endogenous BMP9) programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
CALR Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for CALR Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Matriptase-2 Inhibitor
US/EU buyer target-interest mandate for Matriptase-2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Plasminogen Inhibitor
US/EU buyer target-interest mandate for Plasminogen Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Protein S Inhibitor
US/EU buyer target-interest mandate for Protein S Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
SF3B1 Splicing Modulator
US/EU buyer target-interest mandate for SF3B1 Splicing Modulator programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TIE2 Inhibitor
US/EU buyer target-interest mandate for TIE2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TPO Receptor / MPL Inhibitor
US/EU buyer target-interest mandate for TPO Receptor / MPL Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Oral / Cyclic Peptides
US/EU buyer mandate to in-license oral peptide and cyclic peptide programs. No restriction on development stage or indication. Ex-China / global rights preferred.
Mutant CALR (Calreticulin)
US/EU buyer mandate to in-license programs targeting mutant CALR (calreticulin) for hematologic malignancies. Open to small molecule, biologic, or siRNA modalities; preclinical stage acceptable. Ex-China / global rights preferred.
BBB-Penetrant I&I / CNS Small Molecules
US/EU buyer seeking to in-license blood-brain-barrier (BBB)-penetrant immunology & inflammation (I&I) small molecules, or CNS small molecules for neurodegenerative diseases - particularly assets addressing targets in neuroinflammatory or neurometabolic pathways. Ex-China / global rights preferred.
Cardiovascular - Six Named Indications
Overseas buyer mandate to in-license programs treating cardiovascular disease across six named indications: cardiopulmonary disease, heart failure, atrial fibrillation, stroke, atherosclerosis, and pulmonary hypertension. Preclinical-stage assets acceptable; modality open.
MEK-RAF and KRAS-CYP A (small molecule / molecular glue)
European and American buyer mandate to in-license small-molecule and molecular glue programs targeting MEK-RAF and KRAS-CYP A. Pre-PCC (pre-preclinical-candidate) stage assets are explicitly in scope.
Oral Peptides - Autoimmune & Immune-Related Disease
European and American buyer mandate to in-license oral peptide programs targeting autoimmune and immune-related diseases at near-IND or clinical stage.
First-in-Class Autoimmune Antibodies
European and American buyer mandate to in-license first-in-class (FIC) autoimmune antibody programs at pre-PCC stage. Companion brief to the near-IND oral peptide mandate from the same buyers.
Anti-TRBV9 mAb or TRBV9/CD3 T-Cell Engager
European and American buyer mandate to in-license an IND-stage anti-TRBV9 monoclonal antibody, or a TRBV9/CD3 T-cell engager (TCE). Single-target brief with a firm IND-stage requirement.
TYK2 / JAK / dual TYK2-JAK Inhibitors
European and American buyer mandate to in-license TYK2, JAK, or dual TYK2/JAK small-molecule inhibitors. Preclinical-stage assets acceptable. Expect diligence on JH1 versus JH2 binding and on selectivity across the wider JAK family.
Don't see what you're looking for? We have additional opportunities not listed publicly.
Discuss your criteria with our team